



Statement from SCL-GPI Executive Director Kevin B. Kimble, Esq. on H.R. 3

While SCL-GPI commends the effort to lower drug costs for consumers, we have significant questions regarding the methodology and approach. SCL-GPI will continue to focus on equity and access to quality healthcare. We understand the desire to utilize Quality-Adjusted Life Years (QALY) measurement and other foreign reference pricing models but fear they could negatively impact underserved communities. As we all know, these communities and individuals are often the most in need of pricing relief, but history has shown previous government efforts to provide relief have failed.

Kevin B. Kimble, Esq., Executive Director of SCL-GPI stated, “We urge Congress to tread carefully on implementing new foreign-based pricing models because they have historically not properly accounted for our poorest, under-served, and minority communities. The uniqueness of the U.S. healthcare system and its economy create specific needs for these communities and require a more granular understanding of their capacity to pay for life-saving medications. We hope the bill sponsors will closely examine the past failures of previous programs in addressing pricing relief for those most in need.”